Global Alzheimer’s Therapeutics Market Research Report 2021 Professional Edition
Global Alzheimer’s Therapeutics Market Research Report 2021 Professional Edition
Analysis of the Alzheimer s Therapeutics Market reveals emerging trends, consumer adoption rates, and competitive strategies among leading manufacturers worldwide.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The global Alzheimer’s Therapeutics market was valued at 4460.23 Million USD in 2020 and will grow with a CAGR of 5.81% from 2020 to 2027, based on newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Alzheimer`s disease (AD), also referred to simply as Alzheimer`s, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.Europe is estimated to grow at a rapid pace owing to the high prevalence of AD coupled with ever improving diagnostic capabilities. Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level.
By Market Verdors:
Pfizer
Merck &
Novartis AG
Eisai
H. Lundbeck A/S
AC Immune
TauRx Pharmaceuticals
Actavis plc.
Forest Laboratories
Teva Pharmaceuticals Industries
Janssen Pharmaceutical
GE healthcare
Eli Lilly And Company
DiaGenic ASA
VTV Therapeutics
Hoffman-La Roche
AstraZeneca
Daiichi Sankyo Company
By Types:
Donepezil
Memantine
Rivastigmine
By Applications:
Early to Moderate Stages
Moderate to Severe Stages
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alzheimer’s Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Alzheimer’s Therapeutics Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Donepezil
1.4.3 Memantine
1.4.4 Rivastigmine
1.5 Market by Application
1.5.1 Global Alzheimer’s Therapeutics Market Share by Application: 2022-2027
1.5.2 Early to Moderate Stages
1.5.3 Moderate to Severe Stages
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Alzheimer’s Therapeutics Market
1.8.1 Global Alzheimer’s Therapeutics Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Alzheimer’s Therapeutics Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Alzheimer’s Therapeutics Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Alzheimer’s Therapeutics Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Alzheimer’s Therapeutics Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Alzheimer’s Therapeutics Sales Volume Market Share by Region (2016-2021)
3.2 Global Alzheimer’s Therapeutics Sales Revenue Market Share by Region (2016-2021)
3.3 North America Alzheimer’s Therapeutics Sales Volume
3.3.1 North America Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.3.2 North America Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Alzheimer’s Therapeutics Sales Volume
3.4.1 East Asia Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.5.1 Europe Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.6.1 South Asia Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.7.1 Southeast Asia Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.8.1 Middle East Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.9.1 Africa Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.10.1 Oceania Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.11.1 South America Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.11.2 South America Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Alzheimer’s Therapeutics Sales Volume (2016-2021)
3.12.1 Rest of the World Alzheimer’s Therapeutics Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Alzheimer’s Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Alzheimer’s Therapeutics Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Alzheimer’s Therapeutics Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Alzheimer’s Therapeutics Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Alzheimer’s Therapeutics Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Alzheimer’s Therapeutics Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Alzheimer’s Therapeutics Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Alzheimer’s Therapeutics Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Alzheimer’s Therapeutics Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Alzheimer’s Therapeutics Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Alzheimer’s Therapeutics Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Alzheimer’s Therapeutics Sales Volume Market Share by Type (2016-2021)
14.2 Global Alzheimer’s Therapeutics Sales Revenue Market Share by Type (2016-2021)
14.3 Global Alzheimer’s Therapeutics Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Alzheimer’s Therapeutics Consumption Volume by Application (2016-2021)
15.2 Global Alzheimer’s Therapeutics Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Alzheimer’s Therapeutics Business
16.1 Pfizer
16.1.1 Pfizer Company Profile
16.1.2 Pfizer Alzheimer’s Therapeutics Product Specification
16.1.3 Pfizer Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Merck &
16.2.1 Merck & Company Profile
16.2.2 Merck & Alzheimer’s Therapeutics Product Specification
16.2.3 Merck & Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Novartis AG
16.3.1 Novartis AG Company Profile
16.3.2 Novartis AG Alzheimer’s Therapeutics Product Specification
16.3.3 Novartis AG Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Eisai
16.4.1 Eisai Company Profile
16.4.2 Eisai Alzheimer’s Therapeutics Product Specification
16.4.3 Eisai Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 H. Lundbeck A/S
16.5.1 H. Lundbeck A/S Company Profile
16.5.2 H. Lundbeck A/S Alzheimer’s Therapeutics Product Specification
16.5.3 H. Lundbeck A/S Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 AC Immune
16.6.1 AC Immune Company Profile
16.6.2 AC Immune Alzheimer’s Therapeutics Product Specification
16.6.3 AC Immune Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 TauRx Pharmaceuticals
16.7.1 TauRx Pharmaceuticals Company Profile
16.7.2 TauRx Pharmaceuticals Alzheimer’s Therapeutics Product Specification
16.7.3 TauRx Pharmaceuticals Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Actavis plc.
16.8.1 Actavis plc. Company Profile
16.8.2 Actavis plc. Alzheimer’s Therapeutics Product Specification
16.8.3 Actavis plc. Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Forest Laboratories
16.9.1 Forest Laboratories Company Profile
16.9.2 Forest Laboratories Alzheimer’s Therapeutics Product Specification
16.9.3 Forest Laboratories Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Teva Pharmaceuticals Industries
16.10.1 Teva Pharmaceuticals Industries Company Profile
16.10.2 Teva Pharmaceuticals Industries Alzheimer’s Therapeutics Product Specification
16.10.3 Teva Pharmaceuticals Industries Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Janssen Pharmaceutical
16.11.1 Janssen Pharmaceutical Company Profile
16.11.2 Janssen Pharmaceutical Alzheimer’s Therapeutics Product Specification
16.11.3 Janssen Pharmaceutical Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 GE healthcare
16.12.1 GE healthcare Company Profile
16.12.2 GE healthcare Alzheimer’s Therapeutics Product Specification
16.12.3 GE healthcare Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Eli Lilly And Company
16.13.1 Eli Lilly And Company Company Profile
16.13.2 Eli Lilly And Company Alzheimer’s Therapeutics Product Specification
16.13.3 Eli Lilly And Company Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 DiaGenic ASA
16.14.1 DiaGenic ASA Company Profile
16.14.2 DiaGenic ASA Alzheimer’s Therapeutics Product Specification
16.14.3 DiaGenic ASA Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 VTV Therapeutics
16.15.1 VTV Therapeutics Company Profile
16.15.2 VTV Therapeutics Alzheimer’s Therapeutics Product Specification
16.15.3 VTV Therapeutics Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Hoffman-La Roche
16.16.1 Hoffman-La Roche Company Profile
16.16.2 Hoffman-La Roche Alzheimer’s Therapeutics Product Specification
16.16.3 Hoffman-La Roche Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 AstraZeneca
16.17.1 AstraZeneca Company Profile
16.17.2 AstraZeneca Alzheimer’s Therapeutics Product Specification
16.17.3 AstraZeneca Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.18 Daiichi Sankyo Company
16.18.1 Daiichi Sankyo Company Company Profile
16.18.2 Daiichi Sankyo Company Alzheimer’s Therapeutics Product Specification
16.18.3 Daiichi Sankyo Company Alzheimer’s Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Alzheimer’s Therapeutics Manufacturing Cost Analysis
17.1 Alzheimer’s Therapeutics Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Alzheimer’s Therapeutics
17.4 Alzheimer’s Therapeutics Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Alzheimer’s Therapeutics Distributors List
18.3 Alzheimer’s Therapeutics Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Alzheimer’s Therapeutics (2022-2027)
20.2 Global Forecasted Revenue of Alzheimer’s Therapeutics (2022-2027)
20.3 Global Forecasted Price of Alzheimer’s Therapeutics (2016-2027)
20.4 Global Forecasted Production of Alzheimer’s Therapeutics by Region (2022-2027)
20.4.1 North America Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.3 Europe Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.7 Africa Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.9 South America Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Alzheimer’s Therapeutics Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Alzheimer’s Therapeutics by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.2 East Asia Market Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.3 Europe Market Forecasted Consumption of Alzheimer’s Therapeutics by Countriy
21.4 South Asia Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.5 Southeast Asia Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.6 Middle East Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.7 Africa Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.8 Oceania Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.9 South America Forecasted Consumption of Alzheimer’s Therapeutics by Country
21.10 Rest of the world Forecasted Consumption of Alzheimer’s Therapeutics by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Research Methodology:
Alzheimer s Therapeutics Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|